The Influence of The Light-Activated Titania P25 on Human Breast Cancer Cells

Abstract

Cosmetics and other daily care products contain titanium(IV) oxide (titania). Since multiple risk factors can increase the chance of developing cancer, an evaluation of titania safety has become a matter of concern in recent times. However, it should be pointed out that titania as an efficient photocatalyst has been also applied for inactivation of various pathogens, environmental purification and energy conversion, which might result in significant improvement of human life. Therefore, it is worth considering titania not only as a possible cancer initiator, but also as an efficient solution against cancer cells. Accordingly, in this study, the effect of commercial titania photocatalyst P25 (Degussa/Evonik) on breast adenocarcinoma MCF7 cells (ATCC® HTB-22™, breast adenocarcinoma cell line from human) has been investigated. The cells were treated with titania at doses of 10, 30, and 50 µg/mL under UVA/vis irradiation and in the dark. The significant morphological alterations in living cells were observed for larger doses of titania, such as changes in the shape and the size of cells, the deviation from the normal structure, and an increase in cells’ mortality. Moreover, the effect was significantly higher under irradiation than in the dark confirming strong photocatalytic activity of titania P25. In contrast, the lowest dose of titania (10 µg/mL) did not exhibit a significant impact on MCF7 cells, similarly to the nontreated cells. Accordingly, it has been proposed that locally applied titania might be considered for a cancer therapy after necessary in vivo tests to estimate any possibilities of side effects.